Olivia Vizier

The clinical-stage biopharma unveiled the $74 million series B financing Wednesday, brought in from new investors Slate Path Capital, Palkon Capital, ArrowMark Partners and 683 Capital on top of existing backers like Sporos Bioventures.

Arrowhead Pharmaceuticals has added to its collection of RNA collaborations with a $40 million upfront deal with Horizon Therapeutics.

You might expect to find Dr. Robert Hariri strolling through the headquarters of Celularity, the biotechnology company he founded, outfitted in PPE and sterile paper slippers. But when we caught up with this 62-year-old, physically fit aviator, he was in his light-filled office in the 150,000-square-foot Florham Park, New Jersey facility, wearing a black shirt, black pants, and black boots.

The furthest along is a vaccine candidate co-developed by Pfizer, the U.S.-based pharmaceutical giant, and Valneva SE, a French biotech company. In March, the companies kicked off a Phase 2 trial in 600 people ages 5-65. The vaccine, which would be given in two to three doses, is very similar to LYMErix, but it targets six strains of Lyme

At Fore Biotherapeutics, we are leveraging our functional genomics platform, Foresight, to match populations of patients with rare cancer mutations to targeted therapies that have a high probability of making a difference. Our mission is to provide patients with unaddressed cancer mutations with rapid access to the right medicines.

The BeyondSpring Pharmaceuticals CEO Dr. Lan Huang talks through receiving U.S. FDA and China NMPA acceptance of its new drug application with priority review for use of its lead product Plinabulin. Huang says early clinical data supports Plinabulin as a direct anti-cancer agent in combination with PD1/PDL1 inhibitors in small cell lung cancer.

Getting celiac disease (CD) diagnosed can be a long and difficult path for patients, and with no effective…

Latecomers hope size, price or novel technology mean they can still play an important role in the pandemic

Clene (NASDAQ:CLNN) is developing a novel approach for the treatment of neurodegenerative diseases, such as amyotrophic lateral sclerosis, multiple sclerosis and Parkinson’s disease, using nanocatalysts in order to enhance cellular energy production.

Despite the promise of gene therapies, significant challenges have emerged in the field. Dr Carsten Brunn discusses the current obstacles and opportunities when developing gene therapies.

Valneva has yet to successfully usher its inactivated COVID-19 vaccine across the regulatory finish line, but analysts still see reason to bet on the French vaccine specialist.

The Houston-based preclinical biotech has raised a $15.5 million series A round led by Sporos Bioventures. The funding will go toward bringing Stellanova’s lead antibody into the clinic, building out a discovery platform and growing the team, including leadership hires later this year.

The FDA this week approved Scynexis’ ibrexafungerp tablets, now christened Brexafemme, to treat vaginal yeast infections. The green light marks the first approval in a new class of antifungal drugs in more than 20 years and propels Scynexis into the commercial realm with a potential blockbuster in tow.

But this orphan disease is one of the main reasons the team at Calliditas Therapeutics goes to work every day.

At Fountain, specifically, recent advances in AI have enabled us to spearhead a new unbiased approach to drug discovery and development.  We are using this platform to discover, refine, and advance a pipeline of disease-modifying therapies for age-related diseases, addressing both novel compounds and targets.

“However, the mere presence of antibodies to a virus does not necessarily mean an individual has protective immunity to reinfection,” Ian Chan, CEO of Boston-based biotech developer Abpro, told Healthline.

When Boehringer Ingelheim and OSE Immunotherapeutics teamed up in 2018 to develop OSE’s first-in-class checkpoint inhibitor, it was clear BI had high hopes for the immuno-oncology asset: The closely held German company paid about $18 million upfront but then piled on royalties and milestones, making the deal worth $1.4 billion to OSE.

While vaccines target specific viruses, Dutch start-up Leyden Labs is hunting down commonalities in viral families and working on the delivery of intranasal molecules that can protect humans from both known and future viruses.

Interim blinded data from an ongoing phase 2 clinical trial (NCT04098406) suggest treatment effect of catalytically active nanocrystalline gold (CNM-Au8; Clene Nanomedicine, Salt Lake City, UT) for amyotrophic lateral sclerosis (ALS).

“Candida albicans has been the prominent species causing vaginal yeast infections, however, we are seeing a notable shift in the etiology candidiasis with non-albicans Candida species gaining prominence,” Scynexis Vice President, Clinical Development and Medical Affairs Nkechi Azie, MD, said.

As Celularity makes its most significant clinical progress to date, the company is putting theories born of 20 years of postpartum placental stem cell research into practice. Could the production platform it’s building be the key to accessible, affordable allogeneic cell therapy?

A company called Vaxart is developing a COVID-19 vaccine that comes in the form of a tablet that could be stored at room temperature and even mailed to people at home.

Windtree Therapeutics Chief Executive Officer Craig Fraser called 2020 a transformative and productive year for the Bucks County company focused on the development of life-saving therapeutics for acute cardiovascular and pulmonary disorders.

The company spent roughly three months looking at potential locations for its global headquarters, including Boston and the Washington, D.C., region.

In his 13 years at Genzyme, Michael Wyzga noticed something about East Coast drugmakers. Execs would often jet from Boston or New York to San Francisco to find more assets, and completely miss the work being done in flyover states, like Texas or Wisconsin.

BioSpace recently spoke with Jonathan Rigby, Group CEO of Revolo Biotherapeutics, a biotherapeutic company working to revolutionize the treatment of autoimmune and allergic diseases by achieving superior long-term disease remission through resetting the immune system.